1. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients
    Chiara Giacomelli et al, 2021, Biochemical Pharmacology CrossRef
  2. Dual drug delivery collagen vehicles for modulation of skin fibrosis in vitro
    João Q Coentro et al, 2022, Biomed. Mater. CrossRef
    RAKESH KUMAR YADAV et al, 2022, Asian J Pharm Clin Res CrossRef
  4. Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond
    Erik P. Lillehoj et al, 2022, Front. Immunol. CrossRef
  5. Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis
    Manas Sehgal et al, 2022, Heliyon CrossRef
  6. Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
    Daniela Oatis et al, 2022, IJMS CrossRef
  7. Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis
    Rui Wang et al, 2022, Front. Pharmacol. CrossRef
  8. New insights into methylome alterations and consequences during myofibroblastic differentiation in pulmonary fibrosis
    Arnaud A. Mailleux et al, 2022, Eur Respir J CrossRef
  9. BMP3b Is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts.
    Atsushi Suzuki et al, 2022, Am J Respir Cell Mol Biol CrossRef
  10. Evaluation of Sirtuin 1 Levels in Peripheral Blood Mononuclear Cells of Patients With Idiopathic Pulmonary Fibrosis
    Konstantina Deskata et al, 2022 CrossRef
  11. Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway
    Yang Miao et al, 2022, International Immunopharmacology CrossRef
  12. Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities
    Li-Li Ren et al, 2022, Chemico-Biological Interactions CrossRef
  13. TSSK4 upregulation in alveolar epithelial type-II cells facilitates pulmonary fibrosis through HSP90-AKT signaling restriction and AT-II apoptosis
    Huifang Chen et al, 2021, Cell Death Dis CrossRef
  14. The role of autophagy in idiopathic pulmonary fibrosis: from mechanisms to therapies
    Yue-Liang Yue et al, 2022, Ther Adv Respir Dis CrossRef
  15. Plant miRNA osa-miR172d-5p suppressed lung fibrosis by targeting Tab1
    Motofumi Kumazoe et al, 2023, Sci Rep CrossRef
  16. The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis
    Xijier Qiaolongbatu et al, 2023, DDDT CrossRef
  17. Deficiency of HtrA3 Attenuates Bleomycin-Induced Pulmonary Fibrosis Via TGF-β1/Smad Signaling Pathway
    Guirong Li et al, 2023, Lung CrossRef
  18. Sparganii Rhizoma alleviates pulmonary fibrosis by inhibiting fibroblasts differentiation and epithelial-mesenchymal transition mediated by TGF-β1/ Smad2/3 pathway
    Jing Liu et al, 2023, Journal of Ethnopharmacology CrossRef
  19. Targeting TGF-β/periostin signaling by sesamol ameliorates pulmonary fibrosis and improves lung function and survival
    Satya Krishna Tirunavalli et al, 2023, The Journal of Nutritional Biochemistry CrossRef
  20. Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis
    Nikitha Naomi Dsouza et al, 2023, Inflammopharmacol CrossRef
  21. Repurposing of carvedilol to alleviate lung fibrosis in rats: Repressing of TGF-β1/α-SMA/Smad2/3 and STAT3 gene expressions
    Noha A.T. Abbas et al, 2023, Life Sciences CrossRef
  22. null
    Avanka Gunatilaka et al, 2023 CrossRef
  23. PRDX1 negatively regulates bleomycin-induced pulmonary fibrosis via inhibiting the epithelial-mesenchymal transition and lung fibroblast proliferation in vitro and in vivo
    Hu-Nan Sun et al, 2023, Cell Mol Biol Lett CrossRef